Taşkın Şentürk1, Nergiz Yılmaz1, Gökhan Sargın1, Kutsi Köseoğlu2, Çiğdem Yenisey3. 1. Department of Rheumatology, Adnan Menderes University School of Medicine, Aydın, Turkey. 2. Department of Radiology, Adnan Menderes University School of Medicine, Aydın, Turkey. 3. Department of Biochemistry, Adnan Menderes University School of Medicine, Aydın, Turkey.
Abstract
OBJECTIVE: In rheumatoid arthritis (RA), endothelial dysfunction caused by the inflammatory process increases the risk of cardiovascular disease. Asymmetric Dimethylarginine (ADMA) leads to vascular dysfunction, whereas atherosclerosis and increased ADMA is associated with cardiovascular disease risk factors. Flow-mediated Dilation (FMD) is a radiological method to demonstrate endothelial dysfunction. In the present study, we assessed the availability of ADMA as a marker for endothelial dysfunction in RA patients. ADMA can be used as a simple and cheaper method for the determination of endothelial dysfunction. MATERIAL AND METHODS: Forty patients (1 male, 39 female) diagnosed with RA according to the classification criteria and 29 healthy volunteers (2 males, 27 females) were included in this study. ADMA was studied by enzyme-linked immunosorbent assay (ELISA). Chi-square, Fisher's exact test, Mann-Whitney U test, and Spearman's correlation tests were used for analytical analysis, and p<0.05 was considered as the level of statistical significance. RESULTS: In our study, ADMA levels were significantly higher in RA patients. The ADMA level was inversely correlated with FMD. Although high levels of both C-reactive protein and ADMA were detected in patients with high disease activity, there was no statistically significant difference between these parameters (p=0.18). There were statistically significant negative correlations between FMD and age and disease duration (p=0.01, p=0.01). However, there were no statistically significant correlations with erythrocyte sedimentation rate, rheumatoid factor, and disease activity score (p=0.68). In RA patients, there was a statistically significant positive correlation between disease duration and ADMA, whereas a negative correlation was found between FMD and ADMA (p<0.05). CONCLUSION: Our results support the hypothesis that ADMA may be used in the assessment of endothelial dysfunction in patients with RA. It will be cost-effective when commonly used. ADMA may be used in the assessment of endothelial dysfunction in patients with RA.
OBJECTIVE: In rheumatoid arthritis (RA), endothelial dysfunction caused by the inflammatory process increases the risk of cardiovascular disease. Asymmetric Dimethylarginine (ADMA) leads to vascular dysfunction, whereas atherosclerosis and increased ADMA is associated with cardiovascular disease risk factors. Flow-mediated Dilation (FMD) is a radiological method to demonstrate endothelial dysfunction. In the present study, we assessed the availability of ADMA as a marker for endothelial dysfunction in RApatients. ADMA can be used as a simple and cheaper method for the determination of endothelial dysfunction. MATERIAL AND METHODS: Forty patients (1 male, 39 female) diagnosed with RA according to the classification criteria and 29 healthy volunteers (2 males, 27 females) were included in this study. ADMA was studied by enzyme-linked immunosorbent assay (ELISA). Chi-square, Fisher's exact test, Mann-Whitney U test, and Spearman's correlation tests were used for analytical analysis, and p<0.05 was considered as the level of statistical significance. RESULTS: In our study, ADMA levels were significantly higher in RApatients. The ADMA level was inversely correlated with FMD. Although high levels of both C-reactive protein and ADMA were detected in patients with high disease activity, there was no statistically significant difference between these parameters (p=0.18). There were statistically significant negative correlations between FMD and age and disease duration (p=0.01, p=0.01). However, there were no statistically significant correlations with erythrocyte sedimentation rate, rheumatoid factor, and disease activity score (p=0.68). In RApatients, there was a statistically significant positive correlation between disease duration and ADMA, whereas a negative correlation was found between FMD and ADMA (p<0.05). CONCLUSION: Our results support the hypothesis that ADMA may be used in the assessment of endothelial dysfunction in patients with RA. It will be cost-effective when commonly used. ADMA may be used in the assessment of endothelial dysfunction in patients with RA.
Authors: Fernanda Genre; Raquel López-Mejías; Jose A Miranda-Filloy; Beatriz Carnero-López; Inés Gómez-Acebo; Ricardo Blanco; Rodrigo Ochoa; Javier Rueda; Carlos González-Juanatey; Javier Llorca; Miguel A González-Gay Journal: Clin Exp Rheumatol Date: 2013-06-14 Impact factor: 4.473
Authors: J Goldenberg; M B Ferraz; A P Pessoa; A S Fonseca; A C Carvalho; M O Hilario; E Atra Journal: Int J Cardiol Date: 1992-01 Impact factor: 4.164
Authors: D S Celermajer; K E Sorensen; V M Gooch; D J Spiegelhalter; O I Miller; I D Sullivan; J K Lloyd; J E Deanfield Journal: Lancet Date: 1992-11-07 Impact factor: 79.321
Authors: Ernest Choy; Kandeepan Ganeshalingam; Anne Grete Semb; Zoltán Szekanecz; Michael Nurmohamed Journal: Rheumatology (Oxford) Date: 2014-06-06 Impact factor: 7.580
Authors: Unnikrishnan M Chandrasekharan; Zeneng Wang; Yuping Wu; W H Wilson Tang; Stanley L Hazen; Sihe Wang; M Elaine Husni Journal: Arthritis Res Ther Date: 2018-06-08 Impact factor: 5.156